vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and Skyward Specialty Insurance Group, Inc. (SKWD). Click either name above to swap in a different company.
Skyward Specialty Insurance Group, Inc. is the larger business by last-quarter revenue ($385.6M vs $196.0M, roughly 2.0× Axsome Therapeutics, Inc.). Skyward Specialty Insurance Group, Inc. runs the higher net margin — 11.2% vs -14.6%, a 25.8% gap on every dollar of revenue. On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (65.0% vs 26.7%). Skyward Specialty Insurance Group, Inc. produced more free cash flow last quarter ($402.6M vs $-18.7M). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (61.7% CAGR vs 20.6%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Skyward Specialty Insurance Group, Inc. is a specialty property and casualty insurance provider offering tailored coverage solutions including commercial auto, general liability, professional indemnity, and specialty property policies. It primarily serves small-to-medium enterprises and niche industry segments across the United States, focusing on underwriting complex, hard-to-place risks for underserved client groups.
AXSM vs SKWD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $385.6M |
| Net Profit | $-28.6M | $43.2M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 14.2% |
| Net Margin | -14.6% | 11.2% |
| Revenue YoY | 65.0% | 26.7% |
| Net Profit YoY | 61.9% | 200.1% |
| EPS (diluted) | $-0.55 | $1.03 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $385.6M | ||
| Q3 25 | $171.0M | $382.5M | ||
| Q2 25 | $150.0M | $319.9M | ||
| Q1 25 | $121.5M | $328.5M | ||
| Q4 24 | $118.8M | $304.4M | ||
| Q3 24 | $104.8M | $300.9M | ||
| Q2 24 | $87.2M | $279.9M | ||
| Q1 24 | $75.0M | $265.0M |
| Q4 25 | $-28.6M | $43.2M | ||
| Q3 25 | $-47.2M | $45.9M | ||
| Q2 25 | $-48.0M | $38.8M | ||
| Q1 25 | $-59.4M | $42.1M | ||
| Q4 24 | $-74.9M | $14.4M | ||
| Q3 24 | $-64.6M | $36.7M | ||
| Q2 24 | $-79.3M | $31.0M | ||
| Q1 24 | $-68.4M | $36.8M |
| Q4 25 | -13.8% | 14.2% | ||
| Q3 25 | -27.0% | 15.8% | ||
| Q2 25 | -24.5% | 15.6% | ||
| Q1 25 | -46.9% | 15.7% | ||
| Q4 24 | -61.1% | 6.1% | ||
| Q3 24 | -59.8% | 15.6% | ||
| Q2 24 | -89.5% | 14.4% | ||
| Q1 24 | -89.7% | 17.7% |
| Q4 25 | -14.6% | 11.2% | ||
| Q3 25 | -27.6% | 12.0% | ||
| Q2 25 | -32.0% | 12.1% | ||
| Q1 25 | -48.9% | 12.8% | ||
| Q4 24 | -63.1% | 4.7% | ||
| Q3 24 | -61.7% | 12.2% | ||
| Q2 24 | -91.0% | 11.1% | ||
| Q1 24 | -91.1% | 13.9% |
| Q4 25 | $-0.55 | $1.03 | ||
| Q3 25 | $-0.94 | $1.10 | ||
| Q2 25 | $-0.97 | $0.93 | ||
| Q1 25 | $-1.22 | $1.01 | ||
| Q4 24 | $-1.54 | $0.33 | ||
| Q3 24 | $-1.34 | $0.89 | ||
| Q2 24 | $-1.67 | $0.75 | ||
| Q1 24 | $-1.44 | $0.90 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $168.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $1.0B |
| Total Assets | $689.8M | $4.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $168.5M | ||
| Q3 25 | $325.3M | $160.1M | ||
| Q2 25 | $303.0M | $136.6M | ||
| Q1 25 | $300.9M | $112.9M | ||
| Q4 24 | $315.4M | $121.6M | ||
| Q3 24 | $327.3M | $105.6M | ||
| Q2 24 | $315.7M | $73.0M | ||
| Q1 24 | $331.4M | $85.1M |
| Q4 25 | $88.3M | $1.0B | ||
| Q3 25 | $73.7M | $961.4M | ||
| Q2 25 | $73.1M | $899.9M | ||
| Q1 25 | $53.2M | $850.7M | ||
| Q4 24 | $57.0M | $794.0M | ||
| Q3 24 | $92.9M | $797.5M | ||
| Q2 24 | $102.9M | $723.6M | ||
| Q1 24 | $144.0M | $692.3M |
| Q4 25 | $689.8M | $4.8B | ||
| Q3 25 | $669.3M | $4.6B | ||
| Q2 25 | $639.8M | $4.3B | ||
| Q1 25 | $596.7M | $4.0B | ||
| Q4 24 | $568.5M | $3.7B | ||
| Q3 24 | $561.5M | $3.6B | ||
| Q2 24 | $548.2M | $3.4B | ||
| Q1 24 | $545.7M | $3.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $408.1M |
| Free Cash FlowOCF − Capex | $-18.7M | $402.6M |
| FCF MarginFCF / Revenue | -9.6% | 104.4% |
| Capex IntensityCapex / Revenue | 0.0% | 1.4% |
| Cash ConversionOCF / Net Profit | — | 9.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $755.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $408.1M | ||
| Q3 25 | $1.0M | $171.4M | ||
| Q2 25 | $-32.4M | $88.2M | ||
| Q1 25 | $-43.4M | $96.8M | ||
| Q4 24 | $-26.2M | $305.1M | ||
| Q3 24 | $-18.6M | $168.0M | ||
| Q2 24 | $-30.1M | $21.0M | ||
| Q1 24 | $-53.5M | $94.3M |
| Q4 25 | $-18.7M | $402.6M | ||
| Q3 25 | $988.0K | $168.9M | ||
| Q2 25 | $-32.4M | $87.1M | ||
| Q1 25 | $-43.7M | $96.6M | ||
| Q4 24 | $-26.2M | $300.9M | ||
| Q3 24 | $-18.7M | $167.6M | ||
| Q2 24 | $-30.2M | $18.4M | ||
| Q1 24 | $-53.6M | $94.0M |
| Q4 25 | -9.6% | 104.4% | ||
| Q3 25 | 0.6% | 44.2% | ||
| Q2 25 | -21.6% | 27.2% | ||
| Q1 25 | -36.0% | 29.4% | ||
| Q4 24 | -22.1% | 98.8% | ||
| Q3 24 | -17.9% | 55.7% | ||
| Q2 24 | -34.6% | 6.6% | ||
| Q1 24 | -71.4% | 35.5% |
| Q4 25 | 0.0% | 1.4% | ||
| Q3 25 | 0.0% | 0.6% | ||
| Q2 25 | 0.0% | 0.3% | ||
| Q1 25 | 0.3% | 0.1% | ||
| Q4 24 | 0.0% | 1.4% | ||
| Q3 24 | 0.1% | 0.1% | ||
| Q2 24 | 0.1% | 0.9% | ||
| Q1 24 | 0.1% | 0.1% |
| Q4 25 | — | 9.44× | ||
| Q3 25 | — | 3.73× | ||
| Q2 25 | — | 2.27× | ||
| Q1 25 | — | 2.30× | ||
| Q4 24 | — | 21.18× | ||
| Q3 24 | — | 4.58× | ||
| Q2 24 | — | 0.68× | ||
| Q1 24 | — | 2.56× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
